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Since tight glucose control (TGC) inevitably comes with a
risk of hypoglycemia, Krinsley and Preiser [1] suggest the use
of a stepwise approach to glucose control, which they call
“safe, effective glucose control” (SEGC), and that targets an
intermediate blood glucose level (BGL). SEGC is intended to
decrease the rate of hyperglycemia while reducing the
adverse effects of severe hypoglycemia.
Of note, the randomized controlled trials that showed a
benefit from glucose control have tested only one and the
same BGL target (4.4 to 6.1 mmol/l [80 to 110 mg/dl]) [2,3].
In addition, in these trials conventional insulin treatment was
administered only when the BGL was >12 mmol/L (215
mg/dl), with insulin infusion gradually decreased and stopped
when the BGL fell to <10 mmol/l (180 mg/dl). Accordingly,
the average morning BGL of the conventional treatment
group was approximately 8.5 mmol/l (150 mg/dl). Therefore,
it is difficult to understand why this level is now the
recommended BGL target in what Krinsley and Preiser label
”safe” and “effective” glucose control. Avoiding hypoglycemia
may definitely be “safe”, but advocating a target similar to the
control group of the two trials has definitely not been shown
to be “effective” in improving outcome. It is incorrect advice in
the light of evidence-based medicine (there simply is no
evidence for the benefit of using higher BGL targets) and
could adversely lead to more patients with higher BGLs,
which would eventually worsen outcome [4].
Severe and prolonged hypoglycemia can cause complica-
tions and mortality. Hypoglycemia also occurs more often in
the most severely ill patients and those who have a long
intensive care unit (ICU) stay, but this association does not
suffice to conclude that it actually causes death. Solid
evidence, indeed, for a causal relationship between TGC-
induced brief hypoglycemia in the ICU setting and risk of
death is lacking. In contrast, a retrospective nested case-
control study that carefully matched for type and severity of
illness as well as duration of ICU stay and, thus, for exposure
time to insulin infusions suggested no causal relationship
between hypoglycemia and mortality [5]. Recently,
experimental data indicated that glucose reperfusion, rather
than hypoglycemia itself, is the cause of neuronal damage [6].
Hence, not the period of hypoglycemia itself, but the (over)-
correction with intravenous dextrose may be most harmful.
The advice to tolerate higher BGLs in ICU patients as if this
would be “effective to reduce mortality” and “safer” and, thus,
preferable over TGC with a BGL target of 4.4 to 6.1 mmol/l
(80 to 110 mg/dl) is not based on evidence.
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BGL = blood glucose level; ICU = intensive care unit; SEGC = safe, effective glucose control; TGC = tight glucose control.
Authors’ response
James S Krinsley and Jean-Charles Preiser
Having read the letter to the editor of Schultz and Greet Van
den Berghe in response to our commentary on “safe effective
glucose control” [1], we feel it is important to clarify some
issues.
The intention of our proposal was not to advocate targeting a
high BGL in critically ill patients. Instead, review of the dis-
appointing results of recent prospective trials of tight glucose
control [7] suggests that the outstanding results achieved inPage 2 of 2
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the first Leuven study are not achievable in many other clinical
contexts because of the difficulty in achieving euglycemia
without adverse safety concerns.
The suggestion of 150 mg/dl as the highest acceptable BGL
was based on retrospective studies that reported an
increased mortality in patients having a higher mean blood
glucose during the ICU stay. This target was not tested in the
published interventional studies, but achieved incidentally.
The risks associated with hypoglycaemia during critical illness
are incompletely understood and have been shown to indepen-
dently confer increased risk of mortality [8]. Indeed, intensive
insulin therapy has been associated with lower cerebral
(microdialysis) than blood glucose levels, and with increases in
the concentration of markers of cellular distress [9].
Having the ‘primum non nocere’ of our Grandfather
Hippocrates in mind, the proposed stepwise approach to
glucose control will be easier to implement, certainly safer,
and possibly effective, by the avoidance of the severe side
effects of severe hyperglycemia. As monitoring technology
improves it will be possible for more ICU teams to achieve
the ‘sweet spot ‘ of euglycemia.
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